Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot

• Status: Completed
• Trial end date: 2017-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Clinical randomized clinical trial to assess the effectiveness on walking speed of repeated use of botulinum neurotoxin type A (BoNT/A)in the post-stroke spastic equinovarus foot in three successive infiltrations at 6-month intervals, checking if the sustainability of the effect is greater in incobotulinumtoxin A (Xeomin®) than in onabotulinumtoxinA (Botox®).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Parc de Salut Mar
• Treatments: abobotulinumtoxinA; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• First-ever Ischemic or haemorrhagic stroke

• Time since stroke onset: >6months

• Hemiparesis with equinovarus foot

• No previous BoNT/A

Exclusion Criteria:

• Non-ambulant patients

• Medical contraindications for BoNT/A use that appear in the product information sheet